Key Highlights

  • Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals.
  • The deal was paired with a $132 million private placement.
  • Combined pipeline includes KP-104, briquilimab and KP-701.
  • Cash runway is now projected into the second half of 2028.

Jasper Therapeutics (NASDAQ: JSPR) shares closed up 14% at $0.89 after the company completed an all-stock acquisition of Kira Pharmaceuticals in conjunction with a $132 million private placement.

What Happened

The transaction establishes an immunology-focused biologics pipeline for the combined company, featuring three clinical-stage assets: KP-104, briquilimab, and KP-701.

These programs span transplant medicine, autoimmune disease, and complement-mediated indications, according to the company.

The $132 million private placement was announced alongside the merger and is intended to fund the combined pipeline going forward.

Market Reaction

Jasper Therapeutics, trading below $1 per share, saw its stock gain 14% to close at $0.89 on news of the merger and financing.

The move suggests investors viewed the combined pipeline and the extended capital position favorably, despite the all-stock nature of the deal, which can carry its own dilutive effects for existing shareholders of both companies.

Outlook

The company said the financing extends its projected cash runway into the second half of 2028 and sets the stage for several upcoming clinical milestones across transplant, autoimmune, and complement-mediated indications.

What did Jasper Therapeutics announce?

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals alongside a $132 million private placement.

Why did JSPR shares rise?

Shares closed up 14% at $0.89 following the merger and financing announcement, which extends the company's cash runway into the second half of 2028.

What does the combined pipeline include?

The combined company's pipeline features KP-104, briquilimab, and KP-701, targeting transplant, autoimmune, and complement-mediated indications.